Fig. 7From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisForest plot of time to progression. Subgroup analysis for time to progression. TTP, time to progression; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoproteinBack to article page